Oral cladribine recommended for public reimbursement in Canada

 

The Canadian Agency for Drugs and Technologies in Health (CADTH) has recommended that oral cladribine (Mavenclad) be reimbursed by provincial drug plans for the treatment of relapsing-remitting multiple sclerosis (RRMS). Patients who are eligible for oral cladribine are those with an inadequate response or poor tolerability with one prior disease-modifying therapy (DMT), and who have had at least one relapse within the previous 12 months.

It takes 30 seconds

QUICK POLL

How will the CADTH recommendation for public reimbursement of oral cladribine affect your practice?

TOPICS:
Recommend to a Colleague

Related Posts

Go back to home page